Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 78 of 1,261
  1. US 12161678

    Compositions for fecal floral transplantation and methods for making and using them and device for delivering them

    Finch Therapeutics Holdings LLC · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  2. US 12163192

    Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  3. US 12163168

    Engineered primate cystine/cysteine degrading enzymes for therapeutic uses

    The Board of Regents of the University of Texas System · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  4. US 12163148

    Directed editing of cellular RNA via nuclear delivery of CRISPR/Cas9

    The Regents of the University of California · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  5. US 12163169

    Inducible chimeric cytokine receptors

    Allogene Therapeutics, Inc. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  6. US 12161696

    Methods of treating hemophilic arthropathy using chimeric clotting factors

    BIOVERATIV THERAPEUTICS INC. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  7. US 12161648

    Covalent targeting of E3 ligases

    The Regents of the University of California · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  8. US 12161672

    Chimeric antigen receptor and methods of use thereof

    The Regents of the University of California · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  9. US 12161621

    Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease

    The Regents of the University of Colorado · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  10. US 12161632

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Cumberland Pharmaceuticals Inc. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  11. US 12161620

    Devices and methods for facilitating and controlling use of a medication

    Jazz Pharmaceuticals, Inc. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  12. US 12162837

    Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same

    Mebias Discovery, Inc. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  13. US 12162853

    Synthesis of esuberaprost prodrugs

    United Therapeutics Corporation · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  14. US 12161618

    Methods of identifying and treating patients with HIF-2 inhibitor resistance

    The Board of Regents of the University of Texas System · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  15. US 12161097

    Non-human animals having a humanized signal-regulatory protein gene

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  16. US 12162821

    Treatment of cataplexy

    AXSOME MALTA LTD. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  17. US 12161755

    Sustained release device for treatment of Parkinson's disease and other disorders

    Regents of the University of Minnesota · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  18. US 12161607

    Combination of cannabinoids in the treatment of leukemia

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  19. US 12161724

    Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens

    JANUX THERAPEUTICS, INC. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  20. US 12161717

    CD38 modulating antibody agents

    BLACK BELT THERAPEUTICS LIMITED · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  21. WO 2024249235

    CONJUGUÉS ANTICORPS-MÉDICAMENT D'AGENT DE DÉGRADATION DE BET ANTI-CD33 HUMAIN

    ABBVIE INC [US] · Granted Dec 5, 2024 · Expires Nov 30, 2044

    granted
  22. WO 2024249615

    EXOSOMES DE LAIT BOVIN POUR ADMINISTRER DE LA VITAMINE D

    ABBOTT LAB [US] · Granted Dec 5, 2024 · Expires Nov 30, 2044

    granted
  23. US 2024398790

    TREATING SPONDYLOARTHRITIC CONDITIONS WITH UPADACITINIB

    ABBVIE INC [US] · Granted Dec 5, 2024 · Expires Nov 30, 2044

    granted
  24. US 12157735

    Compounds for targeted degradation of BRD9

    C4 THERAPEUTICS, INC. · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.